Imexpharm Corp 2024 IR
The report highlights Imexpharm's resilient growth in 2024, achieving a gross revenue of VND 2,513 billion and maintaining its leadership in the Vietnamese antibiotic market. The company successfully launched 24 new products and advanced 98 R&D pipelines while expanding its EU-GMP production lines to 12. Significant progress was made in digital transformation with the implementation of SAP S/4HANA Cloud and IFRS standards. Sustainability efforts focused on resource efficiency, resulting in a 10% reduction in energy intensity and a 13% reduction in water use intensity.
Company: Imexpharm Corp
Sector: Manufacturing
Country: Vietnam
Year: 2024
Type: IR
Pages: 111
Back to company
Imexpharm Corp
Annual Report
The report highlights Imexpharm's resilient growth in 2024, achieving a gross revenue of VND 2,513 billion and maintaining its leadership in the Vietnamese antibiotic market. The company successfully launched 24 new products and advanced 98 R&D pipelines while expanding its EU-GMP production lines to 12. Significant progress was made in digital transformation with the implementation of SAP S/4HANA Cloud and IFRS standards. Sustainability efforts focused on resource efficiency, resulting in a 10% reduction in energy intensity and a 13% reduction in water use intensity.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Women in Management
Employees